Smith & Nephew’s (SN) Buy Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of Smith & Nephew (LON:SN) in a research report released on Thursday morning, Marketbeat reports. The brokerage currently has a GBX 1,450 ($18.21) target price on the stock.

Several other analysts have also recently weighed in on SN. JPMorgan Chase & Co. reaffirmed an overweight rating and set a GBX 1,300 ($16.33) price objective on shares of Smith & Nephew in a research report on Thursday, April 18th. Barclays reaffirmed an equal weight rating and issued a GBX 1,150 ($14.45) price target on shares of Smith & Nephew in a research note on Friday, February 9th. Finally, Royal Bank of Canada reissued an outperform rating and set a GBX 1,500 ($18.84) price objective on shares of Smith & Nephew in a research report on Friday, April 5th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of GBX 1,346.20 ($16.91).

Smith & Nephew Trading Up 1.1 %

SN opened at GBX 996.80 ($12.52) on Thursday. Smith & Nephew has a one year low of GBX 887 ($11.14) and a one year high of GBX 1,316.75 ($16.54). The company has a debt-to-equity ratio of 59.11, a current ratio of 1.77 and a quick ratio of 0.84. The business has a 50 day simple moving average of GBX 1,018.36 and a two-hundred day simple moving average of GBX 1,035.12. The firm has a market capitalization of £8.72 billion, a price-to-earnings ratio of 4,153.33, a PEG ratio of 0.46 and a beta of 0.51.

Smith & Nephew Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 22nd. Investors of record on Thursday, March 28th will be issued a $0.23 dividend. This is an increase from Smith & Nephew’s previous dividend of $0.14. The ex-dividend date of this dividend is Thursday, March 28th. This represents a dividend yield of 1.62%. Smith & Nephew’s dividend payout ratio (DPR) is presently 12,500.00%.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.